The US Food & Drug Administration should “consider more fluid and targeted guidance” to provide perspective advanced manufacturing technologies outside of individual product approvals, the National Academies of Science, Engineering & Medicine urges in a set of recommendations detailed in a new report.
The recommendation reflects concern that the Center for Drug Evaluation & Research’s “ability to foster innovation is fundamentally constrained by the center’s formal evaluation of technology only as it applies to specific products